Panbela to Participate in the 34th Annual Roth Conference
March 10 2022 - 8:30AM
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with cancer, announced today that
management will participate in a fireside chat at the 34th Annual
Roth Conference on March 14, 2022, at 11:30AM PT. The webcast will
be available at: https://wsw.com/webcast/roth43/pbla/1805948
To learn more or to schedule a one-on-one meeting with
management, please contact your conference representative or
James@HaydenIR.com.
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce
polyamine metabolic inhibition (PMI) by exploiting an observed high
affinity of the compound for pancreatic ductal adenocarcinoma and
other tumors. The molecule has shown signals of tumor growth
inhibition in clinical studies of US and Australian metastatic
pancreatic cancer patients, demonstrating a median overall survival
(OS) of 12.0 months which is not yet final, and an objective
response rate (ORR) of 48%, both exceeding what is seen typically
with the standard of care of gemcitabine + nab-paclitaxel
suggesting potential complementary activity with the existing
FDA-approved standard chemotherapy regimen. In data evaluated from
clinical studies to date, SBP-101 has not shown exacerbation of
bone marrow suppression and peripheral neuropathy, which can be
chemotherapy-related adverse events. Serious visual adverse events
have been evaluated and patients with a history of retinopathy or
at risk of retinal detachment will be excluded from future SBP-101
studies. The safety data and PMI profile observed in the current
Panbela sponsored clinical trial provides support for continued
evaluation of SBP-101 in a randomized clinical trial. For more
information, please
visit https://clinicaltrials.gov/ct2/show/NCT03412799 .
About PanbelaPanbela Therapeutics, Inc. is a
clinical-stage biopharmaceutical company developing disruptive
therapeutics for patients with urgent unmet medical needs. The
company’s initial product candidate, SBP-101, is for the treatment
of patients with metastatic pancreatic ductal adenocarcinoma, the
most common type of pancreatic cancer and in December 2021
announced positive preclinical data supporting the activity of
SBP-101 in ovarian cancer cell lines. In February of 2022 Panbela
announced it had entered into a definitive agreement to acquire
Cancer Prevention Pharmaceuticals, Inc. The combined entity will
have an expanded pipeline addressing an estimated aggregate $5
billion market opportunity for the areas of initial focus: familial
adenomatous polyposis (FAP), first-line metastatic pancreatic
cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention
and ovarian cancer. Further information can be found
at www.panbela.com. Panbela
Therapeutics, Inc. common stock is listed on The Nasdaq Stock
Market LLC under the symbol PBLA.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains “forward-looking
statements,” including within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: “design,” “expect,” “may,”
“plan,” “potential,” and “seek.” All statements other
than statements of historical fact are statements that should be
deemed forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations, and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results and financial condition may differ
materially and adversely from the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
and financial condition to differ materially from those indicated
in the forward-looking statements include, among others, the
following: ( i ) our ability to obtain additional funding
to complete this randomized clinical trial;
(ii) completion and success of our Phase 1 clinical
trial; (iii) the impact of the current COVID-19 pandemic on
our ability to initiate clinical sites
and complete enrollment in this clinical
trial; (iv) our ability to demonstrate the safety and effectiveness
of our SBP-101 product candidate (v) our ability to obtain
regulatory approvals for our SBP-101 product candidate in the
United States, the European Union or other international markets;
(vi) the market acceptance and level of future sales of our SBP-101
product candidate; (vii) the cost and delays in product development
that may result from changes in regulatory oversight applicable to
our SBP-101 product candidate; (viii) the rate of progress in
establishing reimbursement arrangements with third-party payors;
(ix) the effect of competing technological and market developments;
(x) the costs involved in filing and prosecuting patent
applications and enforcing or defending patent claims; and (xi)
such other factors as discussed in Part I, Item 1A under the
caption “Risk Factors” in our most recent Annual Report on Form
10-K, any additional risks presented in our Quarterly Reports on
Form 10-Q and our Current Reports on Form 8-K. Any forward-looking
statement made by us in this press release is based on information
currently available to us and speaks only as of the date on which
it is made. We undertake no obligation to publicly update any
forward-looking statement or reasons why actual results would
differ from those anticipated in any such forward-looking
statement, whether written or oral, whether as a result
of new information, future developments or otherwise.
Contact Information:
Investors:James CarbonaraHayden IR(646)
755-7412james@haydenir.com
Media:Tammy GroenePanbela Therapeutics, Inc.(952) 479-1196 ext.
170IR@panbela.com
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Apr 2023 to Apr 2024